Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
3.6
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales433,475Millions of yenYear on year +3.6%Progress 49.5%
Operating profit24,030Millions of yenYear on year +4.2%Progress 49.2%
Ordinary income23,446Millions of yenYear on year +2.4%Progress 48.7%
Net income attributable to owners of the parent15,479Millions of yenYear on year +1.4%Progress 48.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥132.31
Financial position at period-end
Total assets477,954Millions of yen
of which net assets 293,788 Millions of yenEquity ratio 61.5%vs. prior year-end +1.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+21,408
Investment-16,256
Financials-9,254
Net change-4,102
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period66,421 Millions of yen
Segment revenueDrugstore business 242,817 Millions of yen (YoY +2.5%), Discount store business 190,657 Millions of yen (YoY +4.9%)
Segment profitDrugstore business 13,808 Millions of yen (YoY +4.0%), Discount store business 10,221 Millions of yen (YoY +4.6%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales876,000 Millions of yen (YoY +4.0%)
Operating profit48,800 Millions of yen (YoY +4.2%)
Ordinary income48,100 Millions of yen (YoY +4.1%)
Net income32,150 Millions of yen (YoY +2.4%)
Revision to Earnings ForecastNone
Annual Dividend Forecast131 Yen → 132 Yen（+0.8%）
Factors Behind Changes in Business Performance
Despite the impact of prolonged rain, typhoons and lower inbound demand, the drugstore business recorded increases in both revenue and profit, driven by the effects of renovations at existing stores and strong performance in the dispensing and EC businesses. In the discount store business, food products, particularly discretionary items, offset the reversal in demand for stockpiled rice.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Impairment loss156 Millions of yen
Breakdown of extraordinary income (loss)Extraordinary income Gain on Sale of Investment Securities 33 Millions of yen, Government subsidies 101 Millions of yen, Other 29 Millions of yen / Extraordinary loss Loss on sale of property, plant and equipment 45 Millions of yen, Impairment Losses 156 Millions of yen, Loss on disposal of fixed assets 74 Millions of yen, Loss on impairment of fixed assets 67 Millions of yen, Disaster-related losses 121 Millions of yen, Other 15 Millions of yen
Depreciation and amortization9,441 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End119,331,184 shares
Treasury Shares at Period-End2,332,985 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 433,475 Millions of yen (YoY +3.6%) |
| Operating profit | 24,030 Millions of yen (YoY +4.2%) |
| Ordinary income | 23,446 Millions of yen (YoY +2.4%) |
| Profit attributable to owners of the parent | 15,479 Millions of yen (YoY +1.4%) |
| Net income per share | ¥132.31 |
| Equity ratio | End of the current fiscal period 61.5% / End of previous period 60.1% |
| Total assets | 477,954 Millions of yen |
| Net assets | 293,788 Millions of yen |
| Cash flows from operating activities | 21,408 Millions of yen |
| Cash flows from investing activities | -16,256 Millions of yen |
| Cash flows from financing activities | -9,254 Millions of yen |
| Cash and cash equivalents at end of period | 66,421 Millions of yen |
| Full-year earnings forecast | Net Sales 876,000 Millions of yen (YoY +4.0%) / Operating profit 48,800 Millions of yen (YoY +4.2%) / Ordinary income 48,100 Millions of yen (YoY +4.1%) / Net income 32,150 Millions of yen (YoY +2.4%) |
| Revision to Earnings Forecast | None |
| Annual Dividend Forecast | 131 Yen → 132 Yen（+0.8%） |
| Segment revenue | Drugstore business 242,817 Millions of yen (YoY +2.5%), Discount store business 190,657 Millions of yen (YoY +4.9%) |
| Segment profit | Drugstore business 13,808 Millions of yen (YoY +4.0%), Discount store business 10,221 Millions of yen (YoY +4.6%) |
| Depreciation and amortization | 9,441 Millions of yen |
| Impairment loss | 156 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on Sale of Investment Securities 33 Millions of yen, Government subsidies 101 Millions of yen, Other 29 Millions of yen / Extraordinary loss Loss on sale of property, plant and equipment 45 Millions of yen, Impairment Losses 156 Millions of yen, Loss on disposal of fixed assets 74 Millions of yen, Loss on impairment of fixed assets 67 Millions of yen, Disaster-related losses 121 Millions of yen, Other 15 Millions of yen |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 119,331,184 shares |
| Treasury Shares at Period-End | 2,332,985 shares |
| Factors Behind Changes in Business Performance | Despite the impact of prolonged rain, typhoons and lower inbound demand, the drugstore business recorded increases in both revenue and profit, driven by the effects of renovations at existing stores and strong performance in the dispensing and EC businesses. In the discount store business, food products, particularly discretionary items, offset the reversal in demand for stockpiled rice. |
Items this document does not state (7)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogChanges in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although prolonged rain, typhoons and lower inbound demand had an impact, renovation work at existing stores, strong performance in the dispensing and EC businesses, and increased sales of food products, particularly discretionary items, pushed up revenue. The company also advanced new store openings and productivity improvement measures.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.